賽意信息(300687.SZ):擬投資約3.3億元建設賽意信息全球研發中心
格隆匯6月9日丨賽意信息(300687.SZ)公佈,公司於2025年6月9日召開第四屆董事會第四次會議,審議通過了《關於投資建設賽意信息全球研發中心的議案》,為滿足公司未來持續發展需要,進一步增強公司的持續研發創新能力和核心競爭力,吸引和穩定優秀科研人才,公司擬投資約3.3億元人民幣建設賽意信息全球研發中心,預計建設週期為30個月。公司董事會授權公司經營管理層辦理本次投資項目相關手續,包括但不限於建築施工合同的談判、簽署,產權證書的辦理,以及根據項目實際進展適度調整投資進度和投資額度等具體事項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.